Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer to hold a virtual summit » 09:50
11/12/20
11/12
09:50
11/12/20
09:50
CFMS

Conformis

$0.67 /

+ (+0.00%)

, PSNL

Personalis

$29.44 /

+0.01 (+0.03%)

, RCEL

Avita Medical

$22.01 /

+0.24 (+1.10%)

, TMDX

TransMedics

$14.03 /

+ (+0.00%)

, XAIR

Beyond Air

$5.20 /

-0.06 (-1.14%)

Fall MedTech Virtual…

Fall MedTech Virtual Summit to be held on November 12.Webcast Link

ShowHide Related Items >><<
XAIR Beyond Air
$5.20 /

-0.06 (-1.14%)

TMDX TransMedics
$14.03 /

+ (+0.00%)

RCEL Avita Medical
$22.01 /

+0.24 (+1.10%)

PSNL Personalis
$29.44 /

+0.01 (+0.03%)

CFMS Conformis
$0.67 /

+ (+0.00%)

CFMS Conformis
$0.67 /

+ (+0.00%)

PSNL Personalis
$29.44 /

+0.01 (+0.03%)

11/12/20 Needham
Personalis price target raised to $32 from $25 at Needham
11/06/20 Oppenheimer
Personalis downgraded to Perform from Outperform at Oppenheimer on valuation
11/06/20 Oppenheimer
Personalis downgraded to Perform from Outperform at Oppenheimer
10/19/20 Citi
Personalis initiated with a Buy at Citi
RCEL Avita Medical
$22.01 /

+0.24 (+1.10%)

08/27/20
Fly Intel: Top five analyst initiations
08/27/20 BofA
Avita Medical assumed with a Buy at BofA
07/09/20 BTIG
Avita Medical price target raised to $41 from $8 at BTIG
07/06/20 Oppenheimer
Avita Medical price target raised to $45 from $9 at Oppenheimer
TMDX TransMedics
$14.03 /

+ (+0.00%)

10/08/20
Fly Intel: Top five analyst downgrades
10/08/20 JPMorgan
TransMedics downgraded to Neutral on 'missed' execution at JPMorgan
10/08/20 JPMorgan
TransMedics downgraded to Neutral from Overweight at JPMorgan
09/29/20 Canaccord
TransMedics story intact despite OCS Heart delay, says Canaccord
XAIR Beyond Air
$5.20 /

-0.06 (-1.14%)

XAIR Beyond Air
$5.20 /

-0.06 (-1.14%)

TMDX TransMedics
$14.03 /

+ (+0.00%)

PSNL Personalis
$29.44 /

+0.01 (+0.03%)

CFMS Conformis
$0.67 /

+ (+0.00%)

  • 24
    Sep
  • 12
    Aug
  • 27
    May
  • 10
    Dec
XAIR Beyond Air
$5.20 /

-0.06 (-1.14%)

TMDX TransMedics
$14.03 /

+ (+0.00%)

PSNL Personalis
$29.44 /

+0.01 (+0.03%)

XAIR Beyond Air
$5.20 /

-0.06 (-1.14%)

TMDX TransMedics
$14.03 /

+ (+0.00%)

Earnings
Beyond Air reports Q2 EPS (30c), consensus (30c) » 16:13
11/11/20
11/11
16:13
11/11/20
16:13
XAIR

Beyond Air

$5.20 /

-0.23 (-4.24%)

Reports Q2 revenue…

Reports Q2 revenue $349,6K, consensus $120K. "Over the past few months we have achieved several significant milestones, both regulatory and clinical, across our development pipeline. Most notably, we filed a PMA for the LungFit(TM) PH system for the treatment of PPHN, which will be subject to the standard 180-day FDA review. If approved, LungFit(TM) PH will be our first commercially available product from the LungFit(TM) platform technology that generates nitric oxide from ambient air. I am very proud and humbled by the resilience and execution of the Beyond Air team, as we have faced many pandemic related setbacks. We are now on a clear path towards recognizing the potential of our LungFit(TM) platform for the treatment of respiratory conditions with the goal of improving the lives of patients," said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.

ShowHide Related Items >><<
XAIR Beyond Air
$5.20 /

-0.23 (-4.24%)

XAIR Beyond Air
$5.20 /

-0.23 (-4.24%)

  • 10
    Dec
XAIR Beyond Air
$5.20 /

-0.23 (-4.24%)

XAIR Beyond Air
$5.20 /

-0.23 (-4.24%)

Hot Stocks
Beyond Air submits premarket approval application to FDA for LungFit PH » 07:41
11/11/20
11/11
07:41
11/11/20
07:41
XAIR

Beyond Air

$5.41 /

-0.15 (-2.70%)

Beyond Air announced the…

Beyond Air announced the submission of a premarket approval application to the U.S. Food and Drug Administration for its LungFit PH to treat persistent pulmonary hypertension of the newborn. FDA guidelines allow for a 180-day review period for a PMA. Beyond Air's LungFit is a cylinder-free, phasic flow nitric oxide generator and delivery system and has been designated as a medical device by the FDA. The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 part per million to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. The LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting and chronic, refractory lung infections in the home setting. With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

ShowHide Related Items >><<
XAIR Beyond Air
$5.41 /

-0.15 (-2.70%)

XAIR Beyond Air
$5.41 /

-0.15 (-2.70%)

  • 10
    Dec
XAIR Beyond Air
$5.41 /

-0.15 (-2.70%)

XAIR Beyond Air
$5.41 /

-0.15 (-2.70%)

Conference/Events
Beyond Air management to meet virtually with Oppenheimer » 04:55
10/30/20
10/30
04:55
10/30/20
04:55
XAIR

Beyond Air

$5.40 /

+0.17 (+3.25%)

Virtual Meeting to be…

Virtual Meeting to be held on October 30 hosted by Oppenheimer.

ShowHide Related Items >><<
XAIR Beyond Air
$5.40 /

+0.17 (+3.25%)

XAIR Beyond Air
$5.40 /

+0.17 (+3.25%)

  • 10
    Dec
XAIR Beyond Air
$5.40 /

+0.17 (+3.25%)

XAIR Beyond Air
$5.40 /

+0.17 (+3.25%)

Over a month ago
Conference/Events
Roth Capital to hold a webinar » 08:30
10/28/20
10/28
08:30
10/28/20
08:30
ACER

Acer Therapeutics

$2.64 /

-0.08 (-2.94%)

, APLS

Apellis

$35.59 /

-0.33 (-0.92%)

, ARDS

Aridis Pharmaceuticals

$6.85 /

-0.19 (-2.70%)

, CRVS

Corvus Pharmaceuticals

$4.07 /

+0.2 (+5.17%)

, CWBR

CohBar

$0.92 /

+0.0169 (+1.87%)

, DRRX

Durect

$1.80 /

-0.065 (-3.49%)

, HEPA

Hepion Pharmaceuticals

$3.39 /

-0.01 (-0.29%)

, HGEN

Humanigen

$10.83 /

-1.17 (-9.75%)

, IMUX

Immunic

$17.52 /

+0.82 (+4.91%)

, LIFE

aTyr Pharma

$3.22 /

-0.025 (-0.77%)

, RDHL

RedHill Biopharma

$9.75 /

-0.11 (-1.12%)

, TFFP

TFF Pharmaceuticals

$14.24 /

+0.01 (+0.07%)

, XAIR

Beyond Air

$5.42 /

-0.18 (-3.21%)

COVID-19 Therapeutics in…

COVID-19 Therapeutics in Development will be held on October 28 at 9 am. Webcast Link

ShowHide Related Items >><<
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CWBR CohBar
$0.92 /

+0.0169 (+1.87%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

09/01/20
Fly Intel: Top five analyst initiations
08/31/20 Stifel
Apellis initiated with a Buy at Stifel
07/20/20 Roth Capital
Apellis initiated with a Buy at Roth Capital
06/16/20 BTIG
Apellis initiated with a Neutral at BTIG
ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

05/15/20 H.C. Wainwright
Aridis Pharmaceuticals price target raised to $11 from $7 at H.C. Wainwright
02/19/20 Roth Capital
Aridis Pharmaceuticals initiated with a Buy at Roth Capital
01/27/20 Cantor Fitzgerald
Cantor sees 'meaningful' coronavirus opportunity for Aridis Pharmaceuticals
12/30/19
Fly Intel: Top five analyst actions
CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

10/05/20 Wedbush
Corvus' COVID-19 program data supports further advancement, says Wedbush
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
03/10/20 H.C. Wainwright
Corvus Pharmaceuticals initiated with a Buy at H.C. Wainwright
12/09/19 Mizuho
Corvus pipeline updates 'can only be additive,' says Mizuho
CWBR CohBar
$0.92 /

+0.0169 (+1.87%)

10/15/20 WBB Securities
CohBar initiated with a Speculative Buy at WBB Securities
10/15/20 WBB Securities
CohBar initiated with a Buy at WBB Securities
09/17/20 Roth Capital
CohBar initiated with a Buy at Roth Capital
05/27/20 Brookline
CohBar initiated with a Buy at Brookline
DRRX Durect
$1.80 /

-0.065 (-3.49%)

10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
10/12/20 Roth Capital
Durect initiated with a Buy at Roth Capital
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/14/20 H.C. Wainwright
Humanigen initiated with a Buy at H.C. Wainwright
IMUX Immunic
$17.52 /

+0.82 (+4.91%)

10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
09/28/20 Roth Capital
Roth Capital encouraged by Immunic update on COVID-19 candidate
09/28/20 Piper Sandler
Immunic news removes safety concerns for IMU-838, says Piper Sandler
LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

08/17/20 H.C. Wainwright
aTyr Pharma upgraded to Buy from Neutral at H.C. Wainwright
06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

09/11/20 BTIG
RedHill Biopharma initiated with a Buy at BTIG
08/14/20 Roth Capital
Roth Capital maintains Buy on RedHill after 'noisy' quarter
07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

10/15/20 Roth Capital
TFF Pharmaceuticals price target raised to $23 from $18 at Roth Capital
08/17/20 Maxim
TFF Pharmaceuticals price target raised to $18 from $12 at Maxim
08/14/20 Roth Capital
TFF Pharmaceuticals price target raised to $18 from $15 at Roth Capital
07/08/20 Maxim
TFF Pharmaceuticals initiated with a Buy at Maxim
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

  • 18
    Sep
  • 05
    Aug
  • 10
    Jun
  • 06
    Feb
  • 09
    Jan
  • 10
    Dec
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

Conference/Events
Beyond Air management to meet virtually with Oppenheimer » 12:05
10/26/20
10/26
12:05
10/26/20
12:05
XAIR

Beyond Air

$5.80 /

-0.12 (-2.03%)

Virtual Meeting to be…

Virtual Meeting to be held on October 30 hosted by Oppenheimer.

ShowHide Related Items >><<
XAIR Beyond Air
$5.80 /

-0.12 (-2.03%)

XAIR Beyond Air
$5.80 /

-0.12 (-2.03%)

  • 10
    Dec
XAIR Beyond Air
$5.80 /

-0.12 (-2.03%)

XAIR Beyond Air
$5.80 /

-0.12 (-2.03%)

Hot Stocks
Beyond Air receives approval to initiate study at 150 ppm Nitric Oxide » 07:18
10/21/20
10/21
07:18
10/21/20
07:18
XAIR

Beyond Air

$6.00 /

+0.08 (+1.35%)

Beyond Air announced that…

Beyond Air announced that it plans to initiate a clinical study of the LungFit system for evaluation of the safety and efficacy of high concentration inhaled NO given intermittently to adults hospitalized with acute viral pneumonia, including SARS-CoV-2. The study will take place in Israel and be a multi-center, open-label, randomized clinical trial with approximately 90 adult patients. The enrolled patients will be randomized in a 1:1 ratio to receive inhalations of 150 ppm NO given intermittently for 40 minutes four times per day for up to seven days in addition to standard supportive treatment; or standard supportive treatment alone. Endpoints related to safety, oxygen saturation, fever and ICU admission, among others, will be assessed.

ShowHide Related Items >><<
XAIR Beyond Air
$6.00 /

+0.08 (+1.35%)

XAIR Beyond Air
$6.00 /

+0.08 (+1.35%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
XAIR Beyond Air
$6.00 /

+0.08 (+1.35%)

  • 10
    Dec
XAIR Beyond Air
$6.00 /

+0.08 (+1.35%)

XAIR Beyond Air
$6.00 /

+0.08 (+1.35%)

Hot Stocks
Beyond Air presents in vivo solid tumor data for in situ cancer vaccination » 10:06
10/19/20
10/19
10:06
10/19/20
10:06
XAIR

Beyond Air

$6.02 /

+0.12 (+2.03%)

Beyond Air announced…

Beyond Air announced additional preclinical data that further suggest endogenous high concentration gNO administered directly to solid tumors may trigger a systemic anti-tumor immune response, a concept that could serve as the basis for an effective immunotherapy. These data were included in a presentation by Hila Confino, PhD of Beyond Air, at the AACR Conference on Tumor Immunology and Immunotherapy, which is being held from October 19th to 20th. In the studies, colon and breast tumor-bearing mice received a single treatment with high concentration gNO intratumorally. The CT26 study mice received either 20,000 or 50,000 ppm gNO for five minutes and the 4T1 study mice received 50,000 ppm gNO for ten minutes. Naive mice, inoculated with the same cancer cells, served as an internal control for each study, with the 4T1 study having an additional control arm of mice treated with nitrogen gas. Up to 21 days after gNO administration to the primary tumor, all mice were inoculated with a challenge tumor and growth of that tumor was tracked. At day 45 in the CT26 study, challenge tumor uptake was observed in 100% of naive mice, 27% of 20,000 ppm gNO mice, and 0% of 50,000 ppm gNO mice, suggesting dose-dependence. With respect to CT26 related mortality at day 45, 25% of naive mice, 73% of 20,000 ppm gNO mice and 100% of 50,000 ppm gNO mice were alive. In the 4T1 study, while tumor take was observed in all mice, tumor take was delayed in the gNO-treated mice compared to both control groups.

ShowHide Related Items >><<
XAIR Beyond Air
$6.02 /

+0.12 (+2.03%)

XAIR Beyond Air
$6.02 /

+0.12 (+2.03%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
XAIR Beyond Air
$6.02 /

+0.12 (+2.03%)

  • 10
    Dec
XAIR Beyond Air
$6.02 /

+0.12 (+2.03%)

XAIR Beyond Air
$6.02 /

+0.12 (+2.03%)

Hot Stocks
Beyond Air presents data on anti-coronavirus activity of nitric oxide » 07:25
10/19/20
10/19
07:25
10/19/20
07:25
XAIR

Beyond Air

$5.90 /

+0.07 (+1.20%)

Beyond Air announced the…

Beyond Air announced the presentation of data from its COVID-19 program at the CHEST Annual Meeting 2020, which is being held virtually from October 18th to 21st. Data presented showed the following: A single 2-hour exposure of OC43 human coronavirus to 250 ppm NO in vitro prior to infection of host cells resulted in a significant reduction in viral infectivity and a significant improvement in host cell viability over 7 days. Exposure of OC43 human coronavirus infected cells to 150-250 ppm NO intermittent exposure regimens resulted in as much as a 46% increase in host cell viability. Exposure of OC43 human coronavirus infected cells to a 150 ppm NO intermittent exposure regimen resulted in complete inhibition of infectivity.

ShowHide Related Items >><<
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

  • 10
    Dec
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

Hot Stocks
Beyond Air presents pilot bronchiolitis data at CHEST annual meeting » 07:12
10/19/20
10/19
07:12
10/19/20
07:12
XAIR

Beyond Air

$5.90 /

+0.07 (+1.20%)

Beyond Air announced the…

Beyond Air announced the presentation of data from its bronchiolitis program at the CHEST Annual Meeting 2020, which is being held virtually from October 18th to 21st. The bronchiolitis pilot study analyzed data from 87 infants across eight medical centers. Subjects were randomized 1:1:1 to standard supportive therapy, 150 parts per million NO + SST and 85 ppm NO + SST. Study treatment was given for 40 minutes, every 4.5 hours, four times per day for up to five days. Results from the study show that the effects of intermittent inhaled NO at 150 ppm were statistically significant compared to both standard therapy and 85 ppm NO in reducing the primary endpoint of time to fit for discharge and the key secondary endpoints of hospital length of stay and time to oxygen saturation of greater than 92%. There were no significant differences observed between the 85 ppm NO arm and SST on any endpoint. All treatment groups had similar safety profiles showing that NO therapy was generally well tolerated with no serious adverse events related to NO therapy.

ShowHide Related Items >><<
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

  • 10
    Dec
XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

XAIR Beyond Air
$5.90 /

+0.07 (+1.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.